{"id":4256,"date":"2020-11-30T00:00:00","date_gmt":"2020-11-30T00:00:00","guid":{"rendered":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/2020\/11\/30\/decline-in-sars-cov-2-antibody-response-seen-over-60-days\/"},"modified":"2020-12-02T16:10:20","modified_gmt":"2020-12-02T16:10:20","slug":"decline-in-sars-cov-2-antibody-response-seen-over-60-days","status":"publish","type":"post","link":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/2020\/11\/30\/decline-in-sars-cov-2-antibody-response-seen-over-60-days\/","title":{"rendered":"Decline in SARS-CoV-2 Antibody Response Seen Over 60 Days"},"content":{"rendered":"<h3>\n<p>More than one in four health care personnel who were positive for SARS-CoV-2 antibodies were seronegative on repeat testing<\/p>\n<\/h3>\n<p><b><\/b><\/p>\n<p><b><\/b><\/p>\n<p>MONDAY, Nov. 30, 2020 (HealthDay News) &#8212; More than one-quarter of health care personnel who were positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies were seronegative on repeat testing about 60 days later, according to research published in the Nov. 27 issue of the U.S. Centers for Disease Control and Prevention <em>Morbidity and Mortality Weekly Report<\/em>.<\/p>\n<p>Wesley H. Self, M.D., from the Vanderbilt University Medical Center in Nashville, Tennessee, and colleagues collected serum specimens from a convenience sample of frontline health care personnel at 13 hospitals and tested for antibodies to SARS-CoV-2 during April 3 to June 19, 2020, and about 60 days later. The percentage of individuals with seroreversion (antibody signal-to-threshold ratio >1.0 at baseline and <1.0 at follow-up) was examined.<strong><\/strong><\/p>\n<p>The researchers found that at baseline, 6.0 percent of 3,248 participants had detectable antibodies to SARS-CoV-2. On repeat testing, 93.6 percent of 156 participants experienced a decline in antibody response, as indicated by a lower signal-to-threshold ratio at follow-up versus baseline; 28.2 percent experienced seroreversion. The likelihood of having antibodies detected at the follow-up test was higher for participants with higher versus lower initial antibody responses.<\/p>\n<p>&#8220;These antibody declines might not equate to loss of protective immunity or increased risk for reinfection; this was not assessed in this study,&#8221; the authors write. &#8220;Cross-sectional seroprevalence studies to evaluate population immunity are likely to underestimate rates of previous infection because antibodies appear to only be detectable for a discrete period of time following infection.&#8221;<\/p>\n<p><a href=\"https:\/\/www.cdc.gov\/mmwr\/volumes\/69\/wr\/mm6947a2.htm?s_cid=mm6947a2_w\" target=\"_blank\" rel=\"noopener noreferrer\">Abstract\/Full Text<\/a><\/p>\n<p><i><\/i><\/p>\n<p><i>Copyright \u00a9 2020 <a href=\"http:\/\/www.healthday.com\/\" target=\"_new\" rel=\"noopener noreferrer\">HealthDay<\/a>. All rights reserved.<\/i><\/p>\n","protected":false},"excerpt":{"rendered":"<p>More than one in four health care personnel who were positive for SARS-CoV-2 antibodies were seronegative on repeat testing<\/p>\n","protected":false},"author":4,"featured_media":4463,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[85],"tags":[100],"acf":[],"_links":{"self":[{"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/posts\/4256"}],"collection":[{"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/comments?post=4256"}],"version-history":[{"count":0,"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/posts\/4256\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/media\/4463"}],"wp:attachment":[{"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/media?parent=4256"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/categories?post=4256"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/ec2-34-224-182-223.compute-1.amazonaws.com\/dermatology.healthcare.pro\/index.php\/wp-json\/wp\/v2\/tags?post=4256"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}